Oncolytics Biotech Inc. Files Form 6-K for January 2025: Key Insights & Compliance

Here are the key insights extracted from the provided section of the financial report:

1. Document Type: This is a Form 6-K, which is a report of a foreign private issuer to the SEC.
2. Filing Date: The report covers the month of January 2025.
3. Registrant Information:

• Company Name: Oncolytics Biotech Inc.
• Commission File Number: 001-38512
• Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

4. Filing Purpose: The report is submitted pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
5. Annual Report Filing:

• The registrant indicates that it files annual reports under Form 20-F.
• It does not file under Form 40-F.

6. Signature Section:

• The report is signed by Kirk Look, who is the Chief Financial Officer of Oncolytics Biotech Inc.
• The signing date is January 15, 2025.

7. Exhibits:

• Exhibit 99.1 is referenced as a "Press Release", indicating that additional information may be available in that document.

8. Legal Compliance: The report includes notes about the regulations governing the submission of Form 6-K, indicating compliance with the SEC's rules regarding paper submissions and foreign issuer requirements.

This document serves as a standard report indicating compliance and basic company information for Oncolytics Biotech Inc. It is important for investors and analysts monitoring the company's regulatory filings and overall compliance status.